H B Fuller

In March 2026 the company announced a global minimum 10% increase across all product lines effective 1 April, with significantly higher adjustments for some technologies and regions, and asked customers to send updated demand forecasts to their account representatives. The stated cause was petrochemical constraints and availability, not mix or brand strength; management described more than forty supplier force majeure notices following Middle East conflict disruption.

The largest commitment is Advanced Medical Solutions: 285p a share, about £659 million of equity and £715 million of enterprise value, agreed on 25 June and structured as a Court-sanctioned scheme. AMS shareholders approved it on 12 August, so what remains is court sanction and clearance rather than votes.

A treatment agent copolymerised from an olefinic glycidyl ether, a vinyl silane and a hydrogen-terminated silicone oil, at roughly equal molar parts, keeps the inorganic thermally conductive filler from separating out of the polymer — a failure that shows up as rising hardness and falling heat dissipation over service life. That is the same problem as the potting work seen from the other side: a filled system is only as good as the coupling between filler and resin.

When the company gave its first customer innovation awards, it picked Anhui Huasun, GAF and Niine — a Chinese solar manufacturer, a US roofing company and an Indian hygiene producer. Those three are the growth pools in the portfolio, and two of them were under pressure in the same quarter of 2026: engineering adhesives grew 3% organically only once solar was stripped out, and hygiene, health and consumables fell 10% on customer inventory tightening and consumer trading down.

Fitch affirmed BB with a stable outlook and put pro forma leverage at about 4.7 times, modestly above its 4.5 times negative sensitivity, expecting deleveraging to follow. The company is therefore entering the integration above the threshold at which its own rating comes under pressure. That is a self-imposed constraint with an external consequence: any shortfall in EBITDA, or any resumption of buybacks, walks it back into the sensitivity. My reading is that the commitment is really to a sequence — close, integrate, deleverage — with acquisitions and repurchases suspended until the ratio is repaired. The dividend is the exception and is being held, at $0.2450 a quarter and 58 consecutive years.

Shingled photovoltaic cells need an adhesive that is conductive, flexible, fast-curing and workable, and the filing states each as a number. The resin is made by condensing silica gel with KH570 silane in alkaline solution; the paste combines 45–55 parts of it with 35–45 parts reactive diluent, 1–3 parts free-radical initiator and 350–450 parts silver powder, and targets shear strength above 3 MPa, glass transition below −50 °C, resistivity under 1×10⁻³ Ω·cm, and cure in under 30 seconds at 110 °C. A low glass transition and a fast cure pull against each other; the resin and diluent design is what buys both.

A June 2026 piece by a company employee on a roofing trade site pitches spray applied canister adhesives at workforce constraints: smaller crews, tighter schedules, less physical strain, consistent results across job-site conditions. One trade placement is not a campaign, but it is the clearest statement of the sales logic in the construction-facing lines, and the logic is productivity of a shrinking crew rather than the bond itself.